INVA · XBRL financial data

Innoviva financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	337	392	331	310	359	411
Gross profit	—	—	—	246	296	308
Research and development	2	1	41	34	14	31
Selling, general and administrative	14	16	64	98	116	113
General and administrative	14	16	—	—	—	—
Total operating expenses	16	17	—	132	129	144
Operating income (loss)	321	375	—	114	167	164
Interest expense	18	19	16	19	22	17
Other income (expense)	(0)	(4)	(3)	(5)	(3)	(3)
Income tax expense (benefit)	60	76	67	14	14	56
Earnings per share, basic USD per share	2.21	3.24	3.07	2.75	0.37	4.02
Earnings per share, diluted USD per share	2.02	2.87	2.37	2.20	0.36	3.30
Weighted average shares, basic millions of shares	101	82	70	65	63	67
Weighted average shares, diluted millions of shares	114	94	95	87	74	85

Fiscal years (INVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	246	202	291	194	305	551
Marketable securities	0	0	—	—	—	—
Inventory	—	0	56	41	34	39
Prepaid and other current assets	2	1	30	22	21	27
Total current assets	342	314	444	344	554	728
Property and equipment, net	0	0	0	0	1	2
Right-of-use asset	—	0	3	3	2	11
Goodwill	—	0	27	18	18	18
Total assets	1,000	926	1,231	1,244	1,301	1,635
Accounts payable	0	0	3	7	2	5
Total current liabilities	6	6	135	38	236	50
Long-term debt	386	395	444	446	256	258
Lease liability, non-current	—	0	2	2	1	11
Retained earnings (accumulated deficit)	(722)	(456)	(205)	(25)	(2)	269
Total stockholders' equity	540	415	566	—	691	1,173
Total liabilities and equity	1,000	926	1,231	1,244	1,301	1,635
Common shares outstanding (cover page) millions of shares	101	70	68	63	63	74

Fiscal years (INVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	2	2	7	6	6	9
Depreciation and amortization	14	14	—	—	—	—
Net cash from operating activities	313	364	202	141	189	197
Purchases of property and equipment	0	0	0	0	0	1
Net cash from investing activities	(315)	44	(57)	(67)	(64)	40
Proceeds from issuing common stock	0	1	0	0	1	3
Share repurchases	0	394	9	76	15	5
Dividends paid	0	0	—	—	—	—
Net cash from financing activities	(30)	(452)	(56)	(172)	(13)	9
Net change in cash	(32)	(45)	90	(98)	111	246

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Mannkind	53	109	(18)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	288	59	(34)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.